Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia

NCT07370922 on ClinicalTrials.gov · last registry update 2026-01-27

Finished 22 November 2025, after enrolling 80 people. Primary outcome, as filed: Change in glycemic variability using continuous glucose monitoring after 6 months.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Ain Shams University
Sponsor type: Other
Enrollment: 80
Started: 2024-11-22
Primary completion: 2025-11-22 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in glycemic variability using continuous glucose monitoring after 6 months.

Conditions studied

Transfusion Dependent Beta Thalassemia

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.